Market bets on whether the Federal Reserve's rate hikes would lead to a recession in 2023 have become a primary focus for the equity markets and for those who trade them.
Gainers
Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.